An investigation on behalf of investors, who currently hold shares of Analogic Corporation (NASDAQ: ALOG), was announced concerning whether the takeover of Analogic Corporation by Altaris Capital Partners, LLC for $84.00 per share is unfair to NASDAQ: ALOG stockholders.

The investigation by a law firm concerns whether certain officers and directors of Analogic Corporation breached their fiduciary duties owed to NASDAQ: ALOG investors in connection with the proposed acquisition.

Peabody, MA based Analogic Corporation designs, manufactures, and sells medical imaging systems, ultrasound and security systems, and subsystems to original equipment manufacturers (OEMs) and end users primarily for the medical and airport security markets worldwide.

On April 10, 2018, Analogic Corporation (NASDAQ:ALOG) and Altaris Capital Partners, LLC, a leading private investment firm with expertise in Analogic's end markets, today announced that the Company and an affiliate of Altaris Capital Partners (together with certain affiliated entities, 'Altaris') have entered into a merger agreement under which Analogic will be acquired by Altaris for $84.00 per share in cash, or approximately $1.1 billion on a fully diluted basis.

However, given that at least one analyst has set the high target price for NASDAQ: ALOG shares at $95.00 per share, theinvestigation concerns whether the offer is unfair to NASDAQ: ALOG stockholders. More specifically, the investigation concerns whether the Analogic Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.